News Takeda's Ninlaro fails phase 3 amyloidosis trial Takeda is discontinuing a trial of its drug Ninlaro in systemic light-chain AL amyloidosis after it did not meet the first of two primary endpoints.
News Takeda’s myeloma drug Ninlaro approved in Europe Takeda has gained European Union approval of its multiple myeloma drug Ninlaro for second line use – joining a wave of new treatments for the incurable condition.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face